Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Change in Accured Expenses (2020 - 2025)

Celularity has reported Change in Accured Expenses over the past 6 years, most recently at $822000.0 for Q3 2025.

  • Quarterly results put Change in Accured Expenses at $822000.0 for Q3 2025, down 79.84% from a year ago — trailing twelve months through Sep 2025 was $15.2 million (up 231.16% YoY), and the annual figure for FY2024 was $12.6 million, up 1220.04%.
  • Change in Accured Expenses for Q3 2025 was $822000.0 at Celularity, down from $6.2 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for CELU hit a ceiling of $6.2 million in Q2 2025 and a floor of -$9.2 million in Q4 2022.
  • Median Change in Accured Expenses over the past 5 years was $888000.0 (2023), compared with a mean of $886263.2.
  • Peak annual rise in Change in Accured Expenses hit 13765.96% in 2021, while the deepest fall reached 785.75% in 2021.
  • Celularity's Change in Accured Expenses stood at -$5.6 million in 2021, then plummeted by 62.37% to -$9.2 million in 2022, then soared by 70.98% to -$2.7 million in 2023, then surged by 302.82% to $5.4 million in 2024, then plummeted by 84.77% to $822000.0 in 2025.
  • The last three reported values for Change in Accured Expenses were $822000.0 (Q3 2025), $6.2 million (Q2 2025), and $2.7 million (Q1 2025) per Business Quant data.